Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study

NCT01872221 is registered in ClinicalTrials.gov with Institut Claudius Regaud as lead sponsor.

NCT NCT01872221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01872221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
Lead sponsor
Institut Claudius Regaud
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2013
Completion date
April 30, 2018
Enrollment
21 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma